BioInvent International AB (BOVNF) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Study Overview: BioInvent International AB, in collaboration with Transgene and Merck Sharp & Dohme LLC, is involved in a clinical trial titled A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors. The study aims to evaluate the safety and efficacy of BT-001, both as a standalone treatment and in combination with pembrolizumab, for patients with various advanced solid tumors. This research is significant as it explores innovative treatment options for challenging cancer types.
Intervention/Treatment: The study tests BT-001, an oncolytic vaccinia virus designed to target and destroy cancer cells, alone and in combination with pembrolizumab, a PD-1 blocking antibody known as KEYTRUDA®. The goal is to enhance the immune response against tumors.
Study Design: This is an interventional study with a non-randomized, sequential model. It is open-label, meaning both researchers and participants know which treatment is being administered. The primary purpose is treatment-focused, aiming to assess the therapeutic potential of the interventions.
Study Timeline: The study was first submitted on January 25, 2021. It was recently updated on November 18, 2025. However, the study has been terminated, which indicates a halt in the trial’s progress.
Market Implications: The termination of this study could impact BioInvent International AB’s stock performance and investor confidence, as it suggests potential challenges in the development of BT-001. Investors may need to consider the competitive landscape and alternative innovations in the oncology sector.
The study is currently marked as terminated, with further details available on the ClinicalTrials portal.
To learn more about BOVNF’s potential, visit the BioInvent International AB drug pipeline page.